New Analysis Suggests , Long-Term Effectiveness , for Wegovy Users .<br />NBC reports that patients taking <br />Novo Nordisk's obesity treatment maintain <br />an average of 10% weight loss over four years.<br />The news potentially boosts the <br />drugmaker's push for Wegovy to be <br />covered by insurers and governments. .<br />The company submitted long-term <br />findings at the European Congress <br />on Obesity in Venice, Italy. .<br />This is the longest study <br />we’ve conducted so far of <br />semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC.<br />We see that once the majority <br />of the weight loss is accrued, <br />you don’t go back and start <br />to increase in weight<br />if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC.<br />According to another analysis published by <br />the drugmaker, approximately 17% of trial participants stopped using the treatment <br />due to side effects like nausea. .<br />The costly treatment ranges from $200 <br />to nearly $2,000 per month in the ten <br />countries where the drug is available.<br />NBC reports that Novo Nordisk was the <br />first drugmaker to market GLP-1 agonists, <br />originally developed as a diabetes treatment, <br />to address record high obesity rates.<br />NBC reports that Novo Nordisk was the <br />first drugmaker to market GLP-1 agonists, <br />originally developed as a diabetes treatment, <br />to address record high obesity rates.<br />Rival Eli Lilly launched its drug <br />Zepbound in the United States <br />in December of 2023. .<br />Neither drugmaker has managed <br />to produce enough of the <br />treatment to meet surging demand
